UCB S.A.
http://www.ucb.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From UCB S.A.
Chinese Firms To Dominate Domestic Cell Therapy Market As Gilead Exits
Gilead’s divestment from a 50-50 joint venture with local partner, which came to light recently, will leave China’s cell therapies market under the total control of domestic players in the coming years.
Newron Weighs Up Partners Or M&A As Excitement Grows Over Antipsychotic
The Italian firm has received "several indications of interest" in evenamide, which is being prepped to go into Phase III for treatment-resistant schizophrenia.
Travere Set For Big Expansion As Filspari Wins Full Approval In IgAN
The drug maker could end up doubling the addressable patient population for Filspari thanks to the new label removing the proteinuria threshold, plus a draft treatment guideline from a kidney disease group.
J&J Interested In ‘Differentiated’ Obesity Assets
“It would be an area of interest to us,” Johnson & Johnson CEO Joaquin Duato said of the obesity space during the Morgan Stanley Healthcare Conference.
Company Information
- Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Celltech Pharmaceuticals, Inc.
- Element Genomics
- Engage Therapeutics, Inc., Ra Pharmaceuticals, Inc.
- Schwarz Pharma
- UCB Biopharma
- Upstate Pharma, LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice